



Transdermal drug delivery technology

Wednesday, 11 July 2007


**OBJ**  
LIMITED

P  
R  
E  
S  
S  
  
R  
E  
L  
E  
A  
S  
E

## POSITIVE RESULTS FOR DELIVERY OF THERAPEUTIC PEPTIDE

OBJ Limited (ASX:OBJ) is pleased to report positive results in a recent study using Dermaportation to deliver a therapeutic peptide.

The study, conducted by Curtin University Department of Pharmacy, investigated the ability of OBJ's drug delivery technology to enhance the delivery of a di-peptide (ALA-TRP) through excised human skin. The results demonstrated that the transdermal delivery of ALA-TRP through human epidermis was increased 28-fold by Dermaportation. Importantly, the study also showed that the peptide was delivered unaltered by Dermaportation.



Therapeutic peptides are molecules made up of 2-100 amino acids that are highly effective and selective in targeting specific biological processes. Peptides can be used to treat a broad range of diseases including cancer, cardiovascular, infection, metabolic diseases and central nervous system disorders.<sup>1</sup> The therapeutic peptide market consists of approximately 40 approved products and generated global revenues of US\$7.2B in 2003.<sup>2</sup> The market is forecast to expand rapidly over the decade to reach US\$20B in 2013, as some of the 670 peptides in development enter the market. Further opportunities exist for therapeutic peptides in the \$4.7B anti-ageing cosmeceutical industry.

Therapeutic peptides are generally delivered by intravenous injection, as they are broken down by the digestive system during oral delivery. Pharmaceutical and biotechnology companies are actively seeking innovative and patient-friendly technologies to enhance the delivery of therapeutic peptides. A large market opportunity exists for an effective transdermal delivery system for therapeutic peptides. Dermaportation has the potential to make the administration of these important peptide drugs more convenient, patient friendly and cost-effective than current delivery methods.

<sup>1</sup> Frost & Sullivan. Therapeutic Peptides in Europe: Finding the Opportunities. California 2004.

<sup>2</sup> Allary C & Pichereau C. Therapeutic Peptides Under the Spotlight. European Biopharmaceutical Review Winter 2005.

**OBJ Limited** (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, WA 6007 Australia

P +61 8 9443 3011 | F +61 8 9443 3866 | W [www.obj.com.au](http://www.obj.com.au) | E [info@obj.com.au](mailto:info@obj.com.au)



Transdermal drug delivery technology

*ENDS*

**For more information:**

Mr Jeffrey Edwards    Managing Director  
Dr Leearne Hinch     COO

**P** +618 9443 3011  
**E** [info@obj.com.au](mailto:info@obj.com.au)  
**W** [www.obj.com.au](http://www.obj.com.au)

**About OBJ:**

OBJ Limited (“OBJ”) is an Australian drug delivery company focused on the development of enhanced transdermal delivery solutions for the global pharmaceutical and cosmetic industries. OBJ’s transdermal drug delivery platforms use electro-magnetic energy fields to control molecular movement and skin permeability without disrupting the skin’s protective barrier. OBJ technology enables faster transdermal delivery of a broad range of pharmaceutical actives including high molecular weight, complex, lipophilic and hydrophilic drugs.

For personal use only

P  
R  
E  
S  
S  
  
R  
E  
L  
E  
A  
S  
E

**OBJ**  
LIMITED